Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
Launched by ALLERGAN · Aug 25, 2010
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males with moderate male-pattern baldness (androgenic alopecia)
- • Females with moderate female pattern hair loss
- • Non-smoker or smoker with at least 30 days abstinence from smoking/using nicotine-containing products
- Exclusion Criteria:
- • Any dermatological condition of the scalp other than androgenic alopecia (males) or female pattern hair loss (females)
- • Use of bimatoprost or other prostaglandin analogs within 3 months
- • Prior use of scalp hair growth treatment (eg, finasteride, minoxidil) within 6 months
- • Any prior hair growth procedures (eg, hair transplant or laser)
- • Blood donation or equivalent blood loss within 90 days
- • History of alcohol or drug addiction
About Allergan
Allergan, a global leader in pharmaceutical innovation, specializes in developing and commercializing a diverse portfolio of advanced therapeutic and aesthetic products. With a commitment to improving the health and well-being of patients, Allergan conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies across various medical fields, including ophthalmology, dermatology, and neuroscience. The company is dedicated to adhering to the highest ethical standards and regulatory guidelines, ensuring that its research not only advances medical science but also meets the needs of healthcare providers and patients worldwide. Through strategic collaborations and a focus on scientific excellence, Allergan continues to drive advancements in treatment options and enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tempe, Arizona, United States
Patients applied
Trial Officials
Medical Director
Study Director
Allergan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials